In Regard to Shuryak et  al

I read with interest the article “Optimized Hypofractionation Can Markedly Improve Tumor Control and Decrease Late Effects for Head and Neck Cancer” by Shuryak et al.1 Although limited to human papillomavirus–negative, radiation therapy–only cases, I believe there is still benefit in further studying this dose-fractionati on scheme. Furthermore, the article is provocative enough to suggest an “optimal” dose-fractionation regime that can extend beyond head and neck (HN) cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research